普罗布考改善AMI患者PCI预后及炎症反应的临床研究

Probucol Improve Prognosis and Inflammation after Percutaneous Coronary Intervention in the Patients with Acute Myocardial Infarction

目的:研究使用普罗布考对急性心肌梗死(AMI)患者冠状动脉介入术(PCI)后预后及炎症反应的作用。方法:AMI患者82例,随机分为普罗布考组(41例)及对照组(41例),两组患者均行冠状动脉造影及PCI治疗。普罗布考组在常规用药基础上加普罗布考500mg/次,每日2次。对照组应用辛伐他汀10mg每晚一次口服。记录所有患者住院期间及出院后30 d内心血管事件。并予以炎症相关生物标志物——肿瘤坏死因子(TNF-α),CD40配体(CD40L),P选择素(Ps)检测。结果:普罗布考组住院期间及出院后30 d累计发生心血管事件3例,与对照组相同(P>0.05)。两组术前CD40L,Ps及TNF-α水平无统计学差异(P>0.05);出院后30 d CD40L,Ps及TNF-α各指标同术前比较均显著下降(P<0.05);普罗布考组出院后30d TNF-α,CD40L,Ps水平较与照组无明显差异(P>0.05)。结论:普罗布考可减轻AMI行PCI治疗患者炎症反应,改善预后。

Objective ：To investigate the value of probucol at prognosis and inflammation after percutaneous coronary intervention （PCI） in the patients with acute myocardial infarction （AMI）. Methods：Eight-two patients with AMI were divided into probucol group （41patients） and control group（41patients） randomly. Probucol group was given Probuco1500mg Bid po; control group given Simvastatin 10mg Qd po. Cardiac events were observed and the levels of tumor necrosis factor-α（ TNF-α）, CD40L , P-selectin（Ps） were analyzed. Results：There were no difference at cardiac events in two groups. The levels of CD40L,Ps and TNF-α of two groups were similar at baseline （ P 〉 0. 05 ）, and that 30d after discharge in two groups were significantly lower than before PCI（ P 〈 0. 05 ）. The levels of TNF-α, CD40L and Ps in probucol group at 30d after discharge were similar with simvastatin group（P 〉 0. 05 ）. Conclusion： Probueol improve prognosis and inflammation after PCI in the patients with AMI.